Cardinal Health Sees Healthy Demand, Despite Modest Commodity Pressure
Cardinal Health tops Q1 2027 estimates, and raises guidance, as robust pharma sales offset petroleum headwinds in medical distribution.
Stocks · News reference
Cardinal Health Q1 2027 Earnings Call Transcript
Cardinal Health (NYSE:CAH) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings
U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook
Cardinal Health reported strong first-quarter fiscal 2027 financial results, exceeding analyst expectations and raising its full-year adjusted earnings guidance.
8-K filing — CARDINAL HEALTH INC (CAH)
Filed: 2026-11-05 AccNo: 0000721371-26-000042 Size: 567 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Cardinal Health Recognized as a First-Time Certified Employer
Cardinal Health is among the companies receiving certification for the first time in a regional program, joining other multinational corporations.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie and Bristol Myers Squibb represent contrasting investment strategies in pharmaceuticals. AbbVie offers faster growth with strong immunology drugs (Skyrizi, Rinvoq) and expanding pipeline, trading at premium valuations with expected net income growth to $14.6B. Bristol Myers Squibb trades at significantly lower multiples with stable oncology/hematology focus but faces a harder recovery timeline. The article recommends AbbVie for investors seeking immediate growth prospects despite higher valuations.